Oncocyte Corp (OCX)

Jan 8, 2025, 8:30 AM EST - 9 days ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 11 days ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 2 months ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 2 months ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 3 months ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 5 months ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 7 months ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 8 months ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 8 months ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 8 months ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 10 months ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 10 months ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 10 months ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 1 year ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 24, 2023, 1:35 PM EDT - 1 year ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Jun 27, 2023, 8:30 AM EDT - 1 year ago

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 1, 2023, 4:15 PM EDT - 1 year ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

May 11, 2023, 8:00 AM EDT - 1 year ago

Oncocyte Reports First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 1 year ago

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 18, 2023, 8:45 AM EDT - 1 year ago

Oncocyte Presents New Data at AACR

Apr 12, 2023, 4:15 PM EDT - 1 year ago

Oncocyte Announces Reduction in Force

Apr 7, 2023, 8:24 AM EDT - 1 year ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 3, 2023, 11:40 AM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 5:00 PM EDT - 1 year ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 29, 2023, 4:01 PM EDT - 1 year ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Feb 22, 2023, 8:00 AM EST - 2 years ago

Oncocyte Completes Razor Genomics Transaction

Dec 16, 2022, 8:19 AM EST - 2 years ago

Oncocyte cuts 40% of staff

Dec 16, 2022, 8:00 AM EST - 2 years ago

Oncocyte Announces Initiatives to Focus Corporate Strategy

Nov 30, 2022, 6:05 PM EST - 2 years ago

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

Nov 30, 2022, 6:00 PM EST - 2 years ago

Oncocyte Announces Executive Leadership Changes

Nov 10, 2022, 9:50 PM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 4:30 PM EST - 2 years ago

Oncocyte Reports Third Quarter 2022 Financial Results

Oct 27, 2022, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Third Quarter 2022 Financial Results

Aug 31, 2022, 4:01 PM EDT - 2 years ago

Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference

Aug 30, 2022, 4:27 PM EDT - 2 years ago

Oncocyte Announces Five-Year VA Contract for DetermaRx

Aug 24, 2022, 8:00 AM EDT - 2 years ago

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Aug 18, 2022, 7:06 AM EDT - 2 years ago

OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buying

SMMT

Aug 11, 2022, 3:03 AM EDT - 2 years ago

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q2 2022 Results - Earnings Call Transcript

Aug 3, 2022, 4:01 PM EDT - 2 years ago

Oncocyte to Participate at Upcoming Investor Conferences

Aug 1, 2022, 5:00 AM EDT - 2 years ago

Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022

Jul 27, 2022, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Second Quarter 2022 Financial Results

Jun 22, 2022, 8:00 AM EDT - 2 years ago

Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

May 26, 2022, 5:00 PM EDT - 2 years ago

Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy

May 11, 2022, 10:07 PM EDT - 2 years ago

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2022 Results - Earning Calls Transcript

May 5, 2022, 8:00 AM EDT - 2 years ago

Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test